Keep knowledgeable with free updates
Merely signal as much as the Prescribed drugs sector myFT Digest — delivered on to your inbox.
The US imported a file $53bn of merchandise used within the prescription drugs and medical trade in March as corporations rushed to construct stockpiles in case Donald Trump hits the sector with tariffs.
Imports of pharma merchandise soared round 160 per cent in March from the identical month the earlier yr, and virtually doubled from February, reaching the best on Census Bureau information stretching again to 2002.
The push to buy completed merchandise and components which can be used to make them is among the earliest indicators of how Trump’s sweeping tariffs on US buying and selling companions are reshaping international enterprise.
Trump has not but introduced levies concentrating on the prescription drugs sector, however corporations are making ready for the chance they may be imposed after the US final month launched a nationwide safety assessment on the topic.
The US president on Monday promised to make European nations pay extra for medicine, whereas calling on pharmaceutical corporations to decrease costs for US shoppers. A White Home official famous, nevertheless, that tariffs on pharma merchandise had been a “separate” matter.
The US and UK mentioned final week they might promptly negotiate “significantly preferential” tariff remedies on medicine and components. The pledge could be contingent on the result of Washington’s prescription drugs sector probe and UK compliance with provide chain safety necessities.
Eire accounted for $28bn of the imports in March, up from $5.5bn in the identical interval the earlier yr. A number of US pharmaceutical corporations have manufacturing websites in Eire — lured partially by Dublin’s comparatively low company tax charge. The nation, which is the third-largest exporter of prescription drugs globally, has roughly 50 US Meals and Drug Administration-approved pharma and biopharma vegetation.
JPMorgan Chase’s Abiel Reinhart mentioned branded drug builders “will be able to use the import stockpile they are building now to cushion the impact of tariffs while they build out US manufacturing”.
Cuts to US company tax charges throughout the earlier Trump administration lowered a few of the incentive to fabricate in Europe, he mentioned, however added that “the volume of production in Europe is still high owing to past investments”.
Plenty of US pharmaceutical teams have just lately made bulletins about increasing home manufacturing. These embrace Eli Lilly, which in February set out plans for $27bn of funding, whereas Johnson & Johnson mentioned in March that it could make investments greater than $55bn in 4 factories.
On a quarterly earnings name this month, Lilly’s chief govt advised buyers that “upon completion” of the corporate’s manufacturing plan, it “will be able to supply medicines for the US market entirely from US facilities, as well as increase the volume of medicines we export”.
Different US pharmaceutical corporations have careworn that they have already got a powerful home manufacturing presence, and that they’ve arrange processes to reply to unstable commerce coverage.
Biogen, a big biotech group, mentioned in its first-quarter outcomes that it “operates a significant manufacturing presence in the US”, whereas Pfizer’s chief monetary officer advised analysts that the corporate had arrange a “cross-functional team” to analyse potential outcomes within the present “fluid environment”.
Merck chief govt Rob Davis advised analysts that whereas the corporate’s “biggest exposure” for tariffs was its blockbuster most cancers drug Keytruda, it had stock within the US to final all of 2025.
Trade figures have warned on the affect of pharmaceutical tariffs, together with the chief govt of Johnson and Johnson who mentioned that they might result in drug shortages.
The US at the moment has no tariffs on many prescription drugs due to a 1994 World Commerce Group commerce deal.
European prescription drugs corporations are additionally boosting their US investments in response to the tariff threats. AstraZeneca mentioned this month it was planning additional funding along with its 11 US manufacturing websites, together with shifting manufacture of Europe-made merchandise to the nation.
UK-listed GSK is planning tens of billions of {dollars} of funding in manufacturing and analysis and improvement within the US over the subsequent 5 years.
Further reporting by Jude Webber in Dublin
